Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04387656 · ClinicalTrials.gov registry record

NCI COVID-19 in Cancer Patients, NCCAPS Study

A clinical trial of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Active
Registry status
1,877
Enrollment target
20
Study locations

NCT04387656 is a study of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,877 participants, above the 1,130-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04387656, a study of Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
1,877 participants
Enrollment target
20
Study locations

Study Summary

This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • OTHER Data Collection
  • OTHER Questionnaire Administration

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Arizona

  • Kingman Regional Medical Center - Kingman
  • Banner Children's at Desert - Mesa
  • Cancer Center at Saint Joseph's - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • Veterans Administration Medical Center - Birmingham - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro

Trial Details

FieldValue
Enrollment Target 1,877 participants
Start Date 2020-06-05
Est. Completion 2026-10-03

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT04387656

The ClinicalTrials.gov registry entry for NCT04387656 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,877 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,130-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (66% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT04387656 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT04387656 about?

NCT04387656 is a clinical study titled "NCI COVID-19 in Cancer Patients, NCCAPS Study". This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help r...

What is the current status of trial NCT04387656?

This trial is currently active not recruiting. The enrollment target is 1,877 participants. The study started on 2020-06-05. Estimated completion is 2026-10-03.

What conditions does trial NCT04387656 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, COVID-19 Infection.

What interventions are being tested in trial NCT04387656?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Data Collection (OTHER), Questionnaire Administration (OTHER).

Who is sponsoring clinical trial NCT04387656?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04387656 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.